Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Reach Markets 'The Insider: Meet the CEO' session (August 2021)
21 slides from Prescient Therapeutics's conference presentation, Aug 4, 2021
Slide 1: Investor Presentation announcement: Reach Markets Meet the CEO
Investor Presentation For personal use only MELBOURNE Australia, 4 August 2021: Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted therapies, cell therapy enhancements and next generation CAR-T therapies, is
Slide 2: About Prescient Therapeutics Limited (Prescient)
About Prescient Therapeutics Limited (Prescient) Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies. For personal use only Cell Therapies OmniCAR: is a universal immune receptor platform enablin
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward- For personal use only looking statements are not histori
Slide 4: Differentiated & Innovative Personalised Therapies in Oncology
For personal use only DIFFERENTIATED & INNOVATIVE PERSONALISED THERAPIES IN ONCOLOGY OUT IN FRONT OF THE BIGGEST WAVE IN ONCOLOGY 1 August 2021
Slide 5: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on
Slide 6: Investment Highlights
Investment Highlights For personal use only Universal, modular platform Well funded to deliver value- overcoming current CAR adding milestones challenges Many shots on goal for 3 highly differentiated next-gen substantial value creation CAR-T programs: 1. AML 2. Her2+ solid tumors 3. GBM PTX-100: FI
Slide 7: Corporate Snapshot
CORPORATE SNAPSHOT Metrics Price Chart For personal use only ASX Ticker PTX Total Issued Capital 640 M shares Listed Options 95.4 M Unlisted Options 12.1 M Share Price1 A$0.19 (US$0.14) Market Capitalisation1 A$121 M (US$90 M) Market Cap fully A$140 M (US$103 M) diluted1 Cash Position2 A$16 M (US$12
Slide 8: Innovative Pipeline in Personalised Medicine
Innovative Pipeline in Personalised Medicine For personal use only Program Discovery Screening Preclinical Phase I Phase IB Phase II OmniCAR AML CD33 & CLL-1 OmniCAR HER2 Breast, Ovarian & Gastric cancers OmniCAR GBM Her2 & EGFRviii Targeted Undisclosed 1 Therapies Cell Therapy Enhancements Undisclo
Slide 9: PTX-100 First in Class Ras Pathway Inhibitor
For personal use only PTX-100 FIRST IN CLASS RAS PATHWAY INHIBITOR 6
Slide 10: PTX-100 Phase 1b Summary
For personal use only PTX-100 PHASE 1B SUMMARY Excellent safety profile Early clinical activity • PTX-100 well tolerated up to • PRs in 2 patients with aggressive and including 2,000 mg/m2 refractory TCL • No SAEs related to PTX-100 • Expected PFS of <4 months on SoC • r/r CTCL: 12 months (19 cycles
Slide 11: Progressing to Expansion Cohort
PROGRESSING TO EXPANSION COHORT Case Study For personal use only • 8 – 12 patients with r/r T cell lymphoma • Folotyn (esp PTCL) • Approved for PTCL • 5,600 cases/year in US • Potential bridge to registration study • US$450,540 per patient, per year • Focussing on sweet spot in an area of considerab
Slide 12: PTX-200 Novel Akt Inhibitor
For personal use only PTX-200 NOVEL AKT INHIBITOR 9
Slide 13: Phase 1b Trial Underway: Acute Myeloid Leukemia
PHASE 1B TRIAL UNDERWAY: ACUTE MYELOID LEUKEMIA For personal use only • PI Professor Jeff Lancet at Moffitt, with Dr Tara Lin at KUMC • 15 patients treated with PTX-200 & cytarabine held constant at 200-400 mg/m2 as continuous infusion • 3 CRs so far Jeffrey E Lancet, M.D. • Currently screening seco
Slide 14: Universal, Next Generation CAR-T
For personal use only Universal, Next Generation CAR-T 11
Slide 15: How does the CAR-T process work?
How does the CAR-T process work? For personal use only 1. 2. Blood is collected from the T- Cells are separated and patient removed 3. T-Cells are genetically altered to have special cancer-recognising receptors 5. called Chimeric Antigen Receptor Patient first receives (CAR) Chemotherapy, and then
Slide 16: OmniCAR: flexible, modular CAR platform
OmniCAR: flexible, modular CAR platform For personal use only Targeting ligand Using any SpyTag targeting Covalent bond ligand… Spy Catcher Associate Professor Professor Daniel J. Powell, Jr Andrew Tsourkas Signalling domain …with any UNARMED ARMED immune cell CAR-T cell CAR-T cell 13
Slide 17: OmniCAR can do what conventional CAR-T cannot
OmniCAR can do what conventional CAR-T cannot For personal use only Conventional CAR-T Can be given any map; Armed with any weapon Multiple deployments Including several at once • Soldier with only one map • Single weapon Full communication and • Only trained to hit one target control at all times,
Slide 18: OmniCAR Platform Business Model
OmniCAR Platform Business Model Developing Collaborate & license For personal use only Next generation to third parties products in-house OmniCAR CD33/CLL1 Potential partner for AML based on Targets Potential partner OmniCAR Her2 based on for Solid Tumours Specific Constructs Potential partner OmniC
Slide 19: Key building blocks to PTX Future Value
Key building blocks to PTX Future Value 1 2 3 For personal use only OmniCAR Cell Therapy Targeted Enhancements therapies • Next generation • Overcome efficiency • PTX-100 universal CAR platform challenges faced by other CAR-T • PTX-200 • AML • Collaboration with Peter • Her2+ solid tumours Mac • GBM
Slide 20: Investment case
Compelling investment case! For personal use only Universal, modular platform Well funded to deliver value- overcoming current CAR adding milestones challenges 3 highly differentiated next-gen Many shots on goal for CAR-T programs: substantial value creation 1. AML 2. Her2+ solid tumors 3. GBM PTX-1
Slide 21: Contact
For personal use only ASX code: PTX www.ptxtherapeutics.com CONTACT Steven Yatomi-Clarke CEO & Managing Director Prescient Therapeutics Limited steven@ptxtherapeutics.com
Prescient Therapeutics — Reach Markets 'The Insider: Meet the CEO' session (August 2021) on 6ix